 Jeffrey B. Matthews
Concepts (522)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| General Surgery | 12 | 2021 | 209 | 3.600 |
Why?
| | Pancreas | 7 | 2017 | 254 | 2.660 |
Why?
| | Pancreatitis, Chronic | 12 | 2021 | 52 | 2.570 |
Why?
| | Sodium-Potassium-Chloride Symporters | 7 | 2012 | 24 | 2.310 |
Why?
| | Specialties, Surgical | 6 | 2021 | 56 | 1.970 |
Why?
| | Islets of Langerhans Transplantation | 13 | 2021 | 217 | 1.960 |
Why?
| | Chlorides | 6 | 2012 | 117 | 1.920 |
Why?
| | Coronavirus Infections | 7 | 2020 | 284 | 1.850 |
Why?
| | Pneumonia, Viral | 7 | 2020 | 310 | 1.850 |
Why?
| | Surgical Procedures, Operative | 5 | 2020 | 187 | 1.780 |
Why?
| | Pandemics | 10 | 2020 | 538 | 1.750 |
Why?
| | Pancreatectomy | 15 | 2021 | 155 | 1.750 |
Why?
| | Digestive System Surgical Procedures | 6 | 2019 | 135 | 1.720 |
Why?
| | Epithelial Cells | 10 | 2012 | 627 | 1.550 |
Why?
| | Colon | 6 | 2012 | 502 | 1.490 |
Why?
| | Endosonography | 6 | 2020 | 133 | 1.380 |
Why?
| | Protein Kinase C | 7 | 2005 | 301 | 1.340 |
Why?
| | Intestinal Mucosa | 11 | 2012 | 895 | 1.310 |
Why?
| | Surgery Department, Hospital | 3 | 2020 | 42 | 1.220 |
Why?
| | Education, Medical, Graduate | 6 | 2020 | 331 | 1.200 |
Why?
| | Quaternary Ammonium Compounds | 4 | 2007 | 89 | 1.180 |
Why?
| | Pancreatitis, Acute Necrotizing | 4 | 2012 | 18 | 1.150 |
Why?
| | Gastroenterostomy | 2 | 2020 | 8 | 1.060 |
Why?
| | Pancreatic Neoplasms | 7 | 2014 | 674 | 1.040 |
Why?
| | Infection Control | 4 | 2020 | 137 | 1.010 |
Why?
| | Humans | 98 | 2021 | 83447 | 1.000 |
Why?
| | Pancreaticoduodenectomy | 7 | 2016 | 85 | 0.950 |
Why?
| | Disaster Planning | 1 | 2021 | 28 | 0.900 |
Why?
| | Patient Selection | 4 | 2020 | 698 | 0.900 |
Why?
| | Truth Disclosure | 2 | 2021 | 86 | 0.890 |
Why?
| | Checklist | 1 | 2021 | 52 | 0.880 |
Why?
| | Judgment | 1 | 2021 | 58 | 0.870 |
Why?
| | Advisory Committees | 2 | 2020 | 87 | 0.860 |
Why?
| | Education, Medical, Continuing | 1 | 2021 | 100 | 0.840 |
Why?
| | Accreditation | 1 | 2020 | 51 | 0.830 |
Why?
| | National Institutes of Health (U.S.) | 3 | 2021 | 107 | 0.810 |
Why?
| | Peptic Ulcer | 1 | 2019 | 19 | 0.810 |
Why?
| | Immune Tolerance | 4 | 2010 | 347 | 0.800 |
Why?
| | Surgical Wound Infection | 3 | 2019 | 181 | 0.800 |
Why?
| | Music | 1 | 2019 | 30 | 0.780 |
Why?
| | Disease Transmission, Infectious | 1 | 2020 | 64 | 0.780 |
Why?
| | Quality of Health Care | 2 | 2020 | 362 | 0.780 |
Why?
| | Health Resources | 1 | 2020 | 79 | 0.780 |
Why?
| | Protein Kinase C-epsilon | 6 | 2010 | 22 | 0.770 |
Why?
| | Cyclic AMP | 3 | 2010 | 280 | 0.760 |
Why?
| | Gastric Outlet Obstruction | 2 | 2017 | 13 | 0.730 |
Why?
| | Tetradecanoylphorbol Acetate | 5 | 2010 | 154 | 0.710 |
Why?
| | Informed Consent | 1 | 2020 | 243 | 0.710 |
Why?
| | Decision Making | 2 | 2020 | 618 | 0.690 |
Why?
| | Spinal Cord Injuries | 1 | 2017 | 51 | 0.690 |
Why?
| | Electronic Health Records | 1 | 2020 | 276 | 0.670 |
Why?
| | Pancreatitis | 4 | 2012 | 129 | 0.670 |
Why?
| | United States | 18 | 2021 | 6316 | 0.650 |
Why?
| | Delivery of Health Care | 1 | 2020 | 317 | 0.630 |
Why?
| | Spinal Cord | 1 | 2017 | 257 | 0.630 |
Why?
| | Triage | 3 | 2020 | 99 | 0.590 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 589 | 0.570 |
Why?
| | Anastomotic Leak | 2 | 2014 | 98 | 0.560 |
Why?
| | Pancreatic Pseudocyst | 1 | 2014 | 23 | 0.560 |
Why?
| | History, 20th Century | 5 | 2021 | 319 | 0.560 |
Why?
| | Pancreatic Fistula | 2 | 2011 | 16 | 0.540 |
Why?
| | Peer Review | 1 | 2013 | 21 | 0.530 |
Why?
| | Transplantation, Autologous | 12 | 2021 | 331 | 0.530 |
Why?
| | Choristoma | 1 | 2014 | 76 | 0.530 |
Why?
| | Endocytosis | 3 | 2010 | 192 | 0.530 |
Why?
| | Gastrointestinal Motility | 1 | 2013 | 32 | 0.520 |
Why?
| | Lactones | 2 | 2003 | 33 | 0.510 |
Why?
| | Capsaicin | 1 | 2012 | 47 | 0.500 |
Why?
| | TRPV Cation Channels | 1 | 2012 | 19 | 0.500 |
Why?
| | Protein Kinase C-delta | 2 | 2010 | 28 | 0.500 |
Why?
| | Potassium Channels | 3 | 2004 | 347 | 0.490 |
Why?
| | Congresses as Topic | 1 | 2013 | 121 | 0.490 |
Why?
| | Carbachol | 4 | 2005 | 39 | 0.480 |
Why?
| | Cholangitis | 1 | 2012 | 22 | 0.480 |
Why?
| | Choledocholithiasis | 1 | 2012 | 10 | 0.480 |
Why?
| | Duodenal Diseases | 1 | 2012 | 23 | 0.480 |
Why?
| | Adenocarcinoma | 2 | 2013 | 1195 | 0.470 |
Why?
| | Workload | 2 | 2020 | 121 | 0.470 |
Why?
| | Postoperative Complications | 7 | 2017 | 2263 | 0.470 |
Why?
| | Specialty Boards | 1 | 2011 | 26 | 0.470 |
Why?
| | Gastrointestinal Diseases | 1 | 2013 | 150 | 0.470 |
Why?
| | Cell Line | 12 | 2012 | 2615 | 0.460 |
Why?
| | Diverticulum | 1 | 2012 | 40 | 0.460 |
Why?
| | Biomedical Research | 2 | 2021 | 354 | 0.460 |
Why?
| | Laparoscopy | 4 | 2020 | 705 | 0.450 |
Why?
| | Periodicals as Topic | 1 | 2013 | 168 | 0.450 |
Why?
| | Clinical Competence | 3 | 2020 | 696 | 0.450 |
Why?
| | Colectomy | 1 | 2012 | 181 | 0.440 |
Why?
| | Internship and Residency | 5 | 2020 | 904 | 0.440 |
Why?
| | Cost Savings | 1 | 2010 | 63 | 0.430 |
Why?
| | Pancreatic Cyst | 1 | 2010 | 39 | 0.420 |
Why?
| | Bile Acids and Salts | 2 | 2011 | 47 | 0.420 |
Why?
| | Blood Glucose | 4 | 2021 | 901 | 0.420 |
Why?
| | Gallbladder Neoplasms | 1 | 2010 | 28 | 0.410 |
Why?
| | Career Choice | 1 | 2011 | 137 | 0.410 |
Why?
| | Clathrin | 1 | 2009 | 29 | 0.410 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2010 | 43 | 0.400 |
Why?
| | Neoadjuvant Therapy | 3 | 2020 | 272 | 0.400 |
Why?
| | Health Expenditures | 1 | 2010 | 79 | 0.400 |
Why?
| | Societies, Medical | 4 | 2020 | 572 | 0.400 |
Why?
| | Program Development | 1 | 2010 | 136 | 0.390 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2010 | 224 | 0.380 |
Why?
| | Universities | 3 | 2019 | 134 | 0.380 |
Why?
| | Cooperative Behavior | 1 | 2010 | 170 | 0.380 |
Why?
| | Critical Care | 3 | 2020 | 362 | 0.370 |
Why?
| | Male | 33 | 2021 | 41899 | 0.360 |
Why?
| | Ultrasonography, Interventional | 2 | 2020 | 116 | 0.350 |
Why?
| | Drainage | 3 | 2015 | 170 | 0.350 |
Why?
| | Chicago | 4 | 2020 | 1452 | 0.350 |
Why?
| | Intestinal Diseases | 2 | 2009 | 82 | 0.340 |
Why?
| | Female | 30 | 2021 | 44784 | 0.340 |
Why?
| | Membrane Proteins | 3 | 2011 | 1207 | 0.340 |
Why?
| | Hospital Mortality | 1 | 2009 | 323 | 0.340 |
Why?
| | Blood Proteins | 1 | 2007 | 160 | 0.340 |
Why?
| | Muscarinic Agonists | 2 | 2005 | 23 | 0.340 |
Why?
| | Islets of Langerhans | 3 | 2021 | 539 | 0.330 |
Why?
| | Abdominal Pain | 4 | 2021 | 127 | 0.330 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2020 | 1187 | 0.320 |
Why?
| | Carcinoma | 1 | 2010 | 440 | 0.320 |
Why?
| | Research Support as Topic | 2 | 2021 | 80 | 0.310 |
Why?
| | Membrane Transport Proteins | 2 | 2005 | 166 | 0.310 |
Why?
| | Risk Assessment | 5 | 2020 | 2284 | 0.310 |
Why?
| | History, 21st Century | 3 | 2021 | 182 | 0.310 |
Why?
| | History, 19th Century | 2 | 2021 | 59 | 0.300 |
Why?
| | Bicarbonates | 1 | 2005 | 70 | 0.300 |
Why?
| | Insulin-Secreting Cells | 2 | 2021 | 405 | 0.300 |
Why?
| | Membrane Glycoproteins | 1 | 2007 | 433 | 0.290 |
Why?
| | Diabetes Mellitus | 1 | 2012 | 757 | 0.290 |
Why?
| | Clotrimazole | 1 | 2004 | 3 | 0.290 |
Why?
| | Charybdotoxin | 1 | 2004 | 8 | 0.290 |
Why?
| | Splenic Artery | 1 | 2004 | 9 | 0.290 |
Why?
| | Dogs | 4 | 2017 | 794 | 0.290 |
Why?
| | Digestive System Abnormalities | 1 | 2004 | 14 | 0.280 |
Why?
| | Thrombin | 1 | 2004 | 59 | 0.280 |
Why?
| | Hemostatics | 1 | 2004 | 49 | 0.280 |
Why?
| | Diarrhea | 1 | 2005 | 207 | 0.280 |
Why?
| | Aneurysm, False | 1 | 2004 | 56 | 0.270 |
Why?
| | Wound Healing | 2 | 2004 | 348 | 0.270 |
Why?
| | Middle Aged | 22 | 2020 | 25596 | 0.270 |
Why?
| | Schools, Medical | 1 | 2005 | 113 | 0.270 |
Why?
| | Gastric Bypass | 1 | 2005 | 105 | 0.270 |
Why?
| | Physics | 1 | 2003 | 20 | 0.260 |
Why?
| | Transplantation | 1 | 2003 | 43 | 0.260 |
Why?
| | Necrosis | 3 | 2012 | 208 | 0.260 |
Why?
| | Ammonia | 1 | 2003 | 40 | 0.260 |
Why?
| | Stents | 3 | 2020 | 382 | 0.250 |
Why?
| | Docosahexaenoic Acids | 1 | 2003 | 34 | 0.250 |
Why?
| | Gastroenterology | 2 | 2016 | 124 | 0.250 |
Why?
| | Collagen | 1 | 2004 | 277 | 0.250 |
Why?
| | Protein Transport | 5 | 2010 | 420 | 0.250 |
Why?
| | Health Care Costs | 1 | 2005 | 226 | 0.250 |
Why?
| | Adult | 20 | 2020 | 25995 | 0.240 |
Why?
| | Treatment Outcome | 14 | 2021 | 7905 | 0.240 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 924 | 0.240 |
Why?
| | Embolization, Therapeutic | 1 | 2004 | 228 | 0.240 |
Why?
| | Obesity, Morbid | 1 | 2005 | 211 | 0.240 |
Why?
| | Tight Junctions | 1 | 2003 | 143 | 0.240 |
Why?
| | Reoperation | 2 | 2017 | 623 | 0.240 |
Why?
| | Ion Channels | 1 | 2004 | 260 | 0.230 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2004 | 384 | 0.230 |
Why?
| | Regeneration | 1 | 2003 | 154 | 0.230 |
Why?
| | History, 15th Century | 1 | 2021 | 6 | 0.230 |
Why?
| | History, 16th Century | 1 | 2021 | 9 | 0.230 |
Why?
| | Biotinylation | 2 | 2012 | 41 | 0.230 |
Why?
| | History, 17th Century | 1 | 2021 | 12 | 0.230 |
Why?
| | History, Medieval | 1 | 2021 | 11 | 0.230 |
Why?
| | Breast Neoplasms | 3 | 2020 | 2779 | 0.230 |
Why?
| | History, 18th Century | 1 | 2021 | 23 | 0.230 |
Why?
| | Isoenzymes | 1 | 2002 | 276 | 0.230 |
Why?
| | History, Ancient | 1 | 2021 | 69 | 0.230 |
Why?
| | Information Services | 1 | 2001 | 28 | 0.230 |
Why?
| | Awards and Prizes | 1 | 2021 | 33 | 0.220 |
Why?
| | Receptor, erbB-2 | 2 | 2020 | 193 | 0.220 |
Why?
| | Rats, Sprague-Dawley | 4 | 2017 | 1370 | 0.220 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 3 | 2007 | 72 | 0.220 |
Why?
| | Societies, Scientific | 1 | 2001 | 43 | 0.220 |
Why?
| | Intestines | 1 | 2004 | 424 | 0.220 |
Why?
| | Anastomosis, Roux-en-Y | 3 | 2012 | 29 | 0.220 |
Why?
| | Geriatric Assessment | 2 | 2014 | 157 | 0.210 |
Why?
| | Critical Illness | 1 | 2003 | 282 | 0.210 |
Why?
| | Immunohistochemistry | 3 | 2012 | 1823 | 0.210 |
Why?
| | Animals | 14 | 2017 | 26985 | 0.210 |
Why?
| | Risk | 2 | 2020 | 700 | 0.210 |
Why?
| | Uncertainty | 1 | 2020 | 58 | 0.210 |
Why?
| | Up-Regulation | 1 | 2003 | 712 | 0.210 |
Why?
| | Efficiency, Organizational | 1 | 2020 | 56 | 0.210 |
Why?
| | Antibody Formation | 1 | 2020 | 207 | 0.210 |
Why?
| | Quality of Life | 3 | 2017 | 1369 | 0.200 |
Why?
| | Hydrogen-Ion Concentration | 3 | 2007 | 554 | 0.200 |
Why?
| | Fatty Liver | 1 | 2021 | 123 | 0.200 |
Why?
| | Pseudomonas aeruginosa | 2 | 2011 | 204 | 0.190 |
Why?
| | Students | 1 | 2020 | 129 | 0.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2313 | 0.190 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 1199 | 0.190 |
Why?
| | Operating Rooms | 1 | 2020 | 120 | 0.190 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2002 | 694 | 0.190 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 166 | 0.180 |
Why?
| | Antibodies, Viral | 1 | 2020 | 344 | 0.180 |
Why?
| | Physician's Role | 1 | 2020 | 186 | 0.180 |
Why?
| | Fasting | 1 | 2018 | 173 | 0.180 |
Why?
| | Health Status | 1 | 2020 | 365 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 4 | 2014 | 2569 | 0.170 |
Why?
| | Internet | 1 | 2020 | 321 | 0.170 |
Why?
| | Blotting, Western | 2 | 2012 | 831 | 0.170 |
Why?
| | Reperfusion Injury | 2 | 2011 | 155 | 0.170 |
Why?
| | Sepsis | 2 | 2011 | 299 | 0.170 |
Why?
| | Gene Expression Regulation | 2 | 2005 | 1941 | 0.170 |
Why?
| | Patient Readmission | 2 | 2017 | 276 | 0.160 |
Why?
| | Attitude of Health Personnel | 2 | 2020 | 646 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2012 | 2100 | 0.150 |
Why?
| | Academic Medical Centers | 3 | 2010 | 393 | 0.150 |
Why?
| | Abdominal Abscess | 1 | 2015 | 18 | 0.150 |
Why?
| | Tissue Preservation | 1 | 2015 | 14 | 0.150 |
Why?
| | Cultural Diversity | 1 | 2016 | 57 | 0.150 |
Why?
| | Medical Staff, Hospital | 1 | 2016 | 113 | 0.150 |
Why?
| | Escherichia coli Infections | 1 | 2015 | 52 | 0.150 |
Why?
| | Sodium-Bicarbonate Symporters | 2 | 2005 | 8 | 0.150 |
Why?
| | Pain, Postoperative | 1 | 2017 | 238 | 0.150 |
Why?
| | Cells, Cultured | 4 | 2005 | 2969 | 0.140 |
Why?
| | Follow-Up Studies | 5 | 2019 | 3877 | 0.140 |
Why?
| | Surgery, Computer-Assisted | 2 | 2017 | 107 | 0.140 |
Why?
| | Pancreatic Hormones | 1 | 2014 | 14 | 0.140 |
Why?
| | Survival Analysis | 4 | 2014 | 1584 | 0.140 |
Why?
| | Chloride Channels | 2 | 2005 | 46 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 940 | 0.130 |
Why?
| | Referral and Consultation | 1 | 2016 | 324 | 0.130 |
Why?
| | Endoscopy | 2 | 2017 | 319 | 0.130 |
Why?
| | Cholangitis, Sclerosing | 1 | 2013 | 43 | 0.130 |
Why?
| | Bryostatins | 2 | 2003 | 15 | 0.130 |
Why?
| | Microscopy, Fluorescence | 3 | 2011 | 443 | 0.130 |
Why?
| | Calcium | 2 | 2012 | 1225 | 0.130 |
Why?
| | Incidence | 3 | 2019 | 1639 | 0.130 |
Why?
| | Macrolides | 2 | 2003 | 32 | 0.130 |
Why?
| | Hormone Replacement Therapy | 1 | 2014 | 73 | 0.130 |
Why?
| | Cell Polarity | 2 | 2005 | 120 | 0.130 |
Why?
| | California | 1 | 2013 | 135 | 0.130 |
Why?
| | Insulin | 4 | 2014 | 1169 | 0.130 |
Why?
| | Diterpenes | 1 | 2012 | 22 | 0.130 |
Why?
| | Risk Factors | 4 | 2017 | 5418 | 0.130 |
Why?
| | Hypersensitivity | 2 | 2007 | 141 | 0.130 |
Why?
| | Acrylamides | 1 | 2012 | 31 | 0.130 |
Why?
| | Databases, Factual | 3 | 2017 | 789 | 0.130 |
Why?
| | Electric Conductivity | 1 | 2012 | 153 | 0.120 |
Why?
| | Pancreatic Diseases | 1 | 2012 | 56 | 0.120 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2014 | 172 | 0.120 |
Why?
| | Abscess | 1 | 2012 | 102 | 0.120 |
Why?
| | Antibiotic Prophylaxis | 2 | 2011 | 79 | 0.120 |
Why?
| | Kidney | 3 | 2009 | 1234 | 0.120 |
Why?
| | Aged | 9 | 2020 | 18508 | 0.120 |
Why?
| | Chronic Pain | 1 | 2013 | 107 | 0.120 |
Why?
| | Time Factors | 4 | 2019 | 5496 | 0.120 |
Why?
| | Jejunum | 1 | 2012 | 104 | 0.120 |
Why?
| | Acute Disease | 1 | 2014 | 862 | 0.120 |
Why?
| | Cell Membrane | 3 | 2005 | 700 | 0.120 |
Why?
| | Duodenum | 1 | 2012 | 106 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2016 | 338 | 0.110 |
Why?
| | Child | 5 | 2021 | 6768 | 0.110 |
Why?
| | Debridement | 1 | 2011 | 66 | 0.110 |
Why?
| | Pseudomonas Infections | 1 | 2011 | 97 | 0.110 |
Why?
| | Conflict of Interest | 1 | 2011 | 64 | 0.110 |
Why?
| | Regional Health Planning | 1 | 2010 | 13 | 0.110 |
Why?
| | National Health Programs | 1 | 2010 | 19 | 0.110 |
Why?
| | Laparoscopes | 1 | 2011 | 17 | 0.110 |
Why?
| | Enzyme Inhibitors | 3 | 2004 | 674 | 0.110 |
Why?
| | Cost Control | 1 | 2010 | 46 | 0.110 |
Why?
| | Research | 2 | 2003 | 258 | 0.110 |
Why?
| | Antineoplastic Agents | 1 | 2002 | 2362 | 0.110 |
Why?
| | Rats | 4 | 2009 | 4351 | 0.110 |
Why?
| | Dopamine | 1 | 2012 | 294 | 0.110 |
Why?
| | Cystadenoma, Mucinous | 1 | 2010 | 8 | 0.110 |
Why?
| | Cystadenoma, Serous | 1 | 2010 | 15 | 0.110 |
Why?
| | Cystadenoma, Papillary | 1 | 2010 | 8 | 0.110 |
Why?
| | Ions | 1 | 2010 | 73 | 0.110 |
Why?
| | Mice, Inbred C57BL | 3 | 2012 | 3180 | 0.110 |
Why?
| | Recurrence | 1 | 2014 | 1196 | 0.110 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 29 | 0.110 |
Why?
| | Financing, Government | 1 | 2010 | 23 | 0.110 |
Why?
| | Polyethylene Glycols | 2 | 2011 | 395 | 0.100 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2010 | 43 | 0.100 |
Why?
| | Neoplasm Staging | 2 | 2020 | 1925 | 0.100 |
Why?
| | Algorithms | 2 | 2012 | 1847 | 0.100 |
Why?
| | Adolescent | 8 | 2019 | 9140 | 0.100 |
Why?
| | Polymers | 1 | 2011 | 230 | 0.100 |
Why?
| | Liver Neoplasms | 2 | 2007 | 634 | 0.100 |
Why?
| | Radiation Injuries, Experimental | 1 | 2009 | 48 | 0.100 |
Why?
| | DNA, Complementary | 2 | 2007 | 410 | 0.100 |
Why?
| | United States Food and Drug Administration | 1 | 2010 | 123 | 0.100 |
Why?
| | Protein Isoforms | 1 | 2010 | 270 | 0.100 |
Why?
| | Autoantigens | 1 | 2010 | 135 | 0.100 |
Why?
| | Membrane Microdomains | 1 | 2009 | 65 | 0.100 |
Why?
| | Intestine, Small | 1 | 2011 | 343 | 0.100 |
Why?
| | Radiation-Protective Agents | 1 | 2009 | 101 | 0.100 |
Why?
| | Adenoviridae | 1 | 2010 | 348 | 0.100 |
Why?
| | RNA Interference | 1 | 2010 | 378 | 0.100 |
Why?
| | Doxorubicin | 2 | 2020 | 296 | 0.090 |
Why?
| | Signal Transduction | 4 | 2005 | 3301 | 0.090 |
Why?
| | Ileum | 1 | 2009 | 191 | 0.090 |
Why?
| | Professional Autonomy | 2 | 2020 | 40 | 0.090 |
Why?
| | Positron-Emission Tomography | 1 | 2010 | 273 | 0.090 |
Why?
| | Liver | 2 | 2012 | 1246 | 0.090 |
Why?
| | Methylamines | 1 | 2007 | 5 | 0.090 |
Why?
| | Rubidium Radioisotopes | 1 | 2007 | 5 | 0.090 |
Why?
| | Reference Values | 2 | 2011 | 702 | 0.090 |
Why?
| | Biological Transport, Active | 1 | 2007 | 104 | 0.090 |
Why?
| | Jejunostomy | 1 | 2007 | 18 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2010 | 225 | 0.090 |
Why?
| | Endoscopy, Digestive System | 1 | 2008 | 78 | 0.090 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2010 | 273 | 0.090 |
Why?
| | Severity of Illness Index | 3 | 2017 | 1778 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2021 | 7644 | 0.090 |
Why?
| | Plasmids | 1 | 2007 | 296 | 0.080 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 453 | 0.080 |
Why?
| | Length of Stay | 2 | 2014 | 697 | 0.080 |
Why?
| | Surgical Instruments | 2 | 2005 | 63 | 0.080 |
Why?
| | Adenosine Triphosphatases | 1 | 2007 | 154 | 0.080 |
Why?
| | Immunization | 1 | 2007 | 164 | 0.080 |
Why?
| | Young Adult | 5 | 2019 | 5970 | 0.080 |
Why?
| | Glucose | 1 | 2009 | 625 | 0.080 |
Why?
| | Protein Kinase C-alpha | 2 | 2004 | 30 | 0.080 |
Why?
| | Carbazoles | 2 | 2004 | 52 | 0.080 |
Why?
| | Enterohepatic Circulation | 1 | 2005 | 4 | 0.080 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2005 | 3 | 0.080 |
Why?
| | 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2005 | 19 | 0.080 |
Why?
| | Survival Rate | 2 | 2014 | 1919 | 0.080 |
Why?
| | Stilbenes | 1 | 2005 | 24 | 0.080 |
Why?
| | Antiporters | 1 | 2005 | 24 | 0.080 |
Why?
| | Autoimmunity | 2 | 2010 | 163 | 0.070 |
Why?
| | Electrophysiology | 2 | 2004 | 440 | 0.070 |
Why?
| | Ohio | 1 | 2005 | 39 | 0.070 |
Why?
| | Biological Transport | 2 | 2004 | 413 | 0.070 |
Why?
| | Blotting, Northern | 1 | 2005 | 272 | 0.070 |
Why?
| | Intestinal Absorption | 1 | 2005 | 138 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2011 | 814 | 0.070 |
Why?
| | Mesenteric Veins | 1 | 2005 | 36 | 0.070 |
Why?
| | Cholinergic Agonists | 1 | 2004 | 9 | 0.070 |
Why?
| | Ischemic Preconditioning | 1 | 2005 | 37 | 0.070 |
Why?
| | Barium | 1 | 2004 | 35 | 0.070 |
Why?
| | Injections, Intralesional | 1 | 2004 | 40 | 0.070 |
Why?
| | Autoimmune Diseases | 1 | 2007 | 233 | 0.070 |
Why?
| | Dissection | 1 | 2005 | 47 | 0.070 |
Why?
| | Membrane Potentials | 2 | 2004 | 484 | 0.070 |
Why?
| | Disease-Free Survival | 2 | 2020 | 1196 | 0.070 |
Why?
| | Age Factors | 1 | 2009 | 1916 | 0.070 |
Why?
| | Phosphorylation | 2 | 2004 | 1158 | 0.070 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2005 | 93 | 0.070 |
Why?
| | Neutrophil Infiltration | 1 | 2004 | 25 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2014 | 6577 | 0.070 |
Why?
| | Myosin Light Chains | 1 | 2003 | 29 | 0.070 |
Why?
| | Salmonella typhimurium | 1 | 2004 | 35 | 0.070 |
Why?
| | Drug Combinations | 1 | 2004 | 245 | 0.070 |
Why?
| | Biliary Fistula | 1 | 2003 | 8 | 0.070 |
Why?
| | Microscopy, Electron | 1 | 2004 | 534 | 0.070 |
Why?
| | Suture Techniques | 1 | 2005 | 136 | 0.070 |
Why?
| | Chlorine | 1 | 2003 | 13 | 0.070 |
Why?
| | Indoles | 2 | 2004 | 335 | 0.070 |
Why?
| | Stimulation, Chemical | 1 | 2003 | 68 | 0.070 |
Why?
| | Radioisotopes | 1 | 2003 | 40 | 0.070 |
Why?
| | Mice | 3 | 2012 | 11133 | 0.070 |
Why?
| | Quantum Theory | 1 | 2003 | 27 | 0.070 |
Why?
| | Ultrasonics | 1 | 2003 | 34 | 0.070 |
Why?
| | Dinoprostone | 1 | 2003 | 70 | 0.070 |
Why?
| | Fatal Outcome | 1 | 2004 | 308 | 0.070 |
Why?
| | Growth Substances | 1 | 2003 | 88 | 0.070 |
Why?
| | Chimera | 1 | 2003 | 56 | 0.070 |
Why?
| | Professional Practice | 1 | 2003 | 54 | 0.060 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2003 | 86 | 0.060 |
Why?
| | Tritium | 1 | 2002 | 140 | 0.060 |
Why?
| | Focal Adhesions | 1 | 2003 | 69 | 0.060 |
Why?
| | Thapsigargin | 1 | 2002 | 54 | 0.060 |
Why?
| | Mannitol | 1 | 2002 | 51 | 0.060 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2002 | 46 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2010 | 2674 | 0.060 |
Why?
| | Electric Impedance | 1 | 2003 | 102 | 0.060 |
Why?
| | Ion Transport | 1 | 2003 | 84 | 0.060 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2002 | 84 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2005 | 409 | 0.060 |
Why?
| | Cell Membrane Permeability | 1 | 2003 | 133 | 0.060 |
Why?
| | Epithelium | 1 | 2003 | 321 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2016 | 300 | 0.060 |
Why?
| | Tumor Cells, Cultured | 1 | 2004 | 1088 | 0.060 |
Why?
| | Carcinogens | 1 | 2002 | 109 | 0.060 |
Why?
| | Iodine Radioisotopes | 1 | 2002 | 147 | 0.060 |
Why?
| | Microfilament Proteins | 1 | 2004 | 207 | 0.060 |
Why?
| | Radiography | 1 | 2004 | 873 | 0.060 |
Why?
| | Drug Interactions | 1 | 2002 | 271 | 0.060 |
Why?
| | Potassium | 1 | 2003 | 308 | 0.060 |
Why?
| | Liver Diseases | 1 | 2004 | 227 | 0.060 |
Why?
| | Education, Medical | 1 | 2005 | 213 | 0.060 |
Why?
| | Cystic Fibrosis | 1 | 2003 | 128 | 0.060 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1087 | 0.060 |
Why?
| | Ultrasonography | 1 | 2004 | 696 | 0.060 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 296 | 0.060 |
Why?
| | Cell Division | 1 | 2003 | 750 | 0.060 |
Why?
| | Cytoskeleton | 1 | 2002 | 192 | 0.060 |
Why?
| | Reconstructive Surgical Procedures | 1 | 2005 | 272 | 0.050 |
Why?
| | Body Mass Index | 1 | 2005 | 784 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2020 | 79 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2003 | 395 | 0.050 |
Why?
| | Social Problems | 1 | 2020 | 10 | 0.050 |
Why?
| | Antigens, CD | 1 | 2002 | 484 | 0.050 |
Why?
| | Bacterial Adhesion | 2 | 2011 | 92 | 0.050 |
Why?
| | Organizational Innovation | 1 | 2020 | 36 | 0.050 |
Why?
| | Cell Movement | 1 | 2004 | 745 | 0.050 |
Why?
| | Education, Distance | 1 | 2020 | 23 | 0.050 |
Why?
| | Epidemics | 1 | 2020 | 36 | 0.050 |
Why?
| | Taxoids | 1 | 2020 | 131 | 0.050 |
Why?
| | Computer-Assisted Instruction | 1 | 2020 | 48 | 0.050 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2003 | 319 | 0.050 |
Why?
| | Colonic Neoplasms | 1 | 2004 | 561 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2020 | 290 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 132 | 0.050 |
Why?
| | Virulence | 2 | 2011 | 274 | 0.050 |
Why?
| | Actins | 1 | 2002 | 434 | 0.050 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2020 | 80 | 0.050 |
Why?
| | Colorectal Neoplasms | 1 | 2007 | 858 | 0.050 |
Why?
| | Cytokines | 1 | 2003 | 753 | 0.050 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 23 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 2080 | 0.050 |
Why?
| | Receptors, Steroid | 1 | 2019 | 45 | 0.050 |
Why?
| | C-Peptide | 1 | 2018 | 173 | 0.050 |
Why?
| | Violence | 1 | 2020 | 117 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2020 | 482 | 0.050 |
Why?
| | Cross Infection | 1 | 2020 | 192 | 0.040 |
Why?
| | Health Personnel | 1 | 2020 | 183 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2020 | 870 | 0.040 |
Why?
| | Prospective Studies | 2 | 2018 | 4085 | 0.040 |
Why?
| | Risk Adjustment | 1 | 2017 | 29 | 0.040 |
Why?
| | Organ Transplantation | 1 | 2001 | 278 | 0.040 |
Why?
| | Hypoglycemic Agents | 2 | 2014 | 380 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2019 | 320 | 0.040 |
Why?
| | Learning | 1 | 2020 | 262 | 0.040 |
Why?
| | Sex Factors | 1 | 2021 | 1090 | 0.040 |
Why?
| | Propensity Score | 1 | 2017 | 131 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2004 | 898 | 0.040 |
Why?
| | Stress, Psychological | 1 | 2020 | 308 | 0.040 |
Why?
| | Paclitaxel | 1 | 2019 | 464 | 0.040 |
Why?
| | Pain Management | 1 | 2017 | 128 | 0.040 |
Why?
| | Cultural Competency | 1 | 2016 | 27 | 0.040 |
Why?
| | Palliative Care | 1 | 2017 | 254 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 1434 | 0.040 |
Why?
| | Models, Biological | 1 | 2003 | 1798 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2016 | 331 | 0.040 |
Why?
| | Program Evaluation | 1 | 2016 | 301 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2016 | 301 | 0.040 |
Why?
| | Educational Measurement | 1 | 2016 | 208 | 0.040 |
Why?
| | Narcotics | 1 | 2014 | 70 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 566 | 0.030 |
Why?
| | Frail Elderly | 1 | 2014 | 64 | 0.030 |
Why?
| | Quality Improvement | 1 | 2017 | 364 | 0.030 |
Why?
| | Apoptosis | 2 | 2011 | 1775 | 0.030 |
Why?
| | Asthma | 1 | 2001 | 889 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2013 | 194 | 0.030 |
Why?
| | Hepatectomy | 2 | 2004 | 154 | 0.030 |
Why?
| | Illinois | 1 | 2014 | 467 | 0.030 |
Why?
| | Deoxycholic Acid | 1 | 2011 | 10 | 0.030 |
Why?
| | Bacterial Translocation | 1 | 2011 | 46 | 0.030 |
Why?
| | Financial Support | 1 | 2011 | 7 | 0.030 |
Why?
| | Phenols | 1 | 2011 | 39 | 0.030 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2011 | 30 | 0.030 |
Why?
| | Benzhydryl Compounds | 1 | 2011 | 42 | 0.030 |
Why?
| | Caco-2 Cells | 1 | 2011 | 145 | 0.030 |
Why?
| | Caspase 3 | 1 | 2011 | 175 | 0.030 |
Why?
| | Random Allocation | 1 | 2011 | 376 | 0.030 |
Why?
| | Organizational Policy | 1 | 2011 | 56 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2013 | 1021 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 375 | 0.030 |
Why?
| | Chronic Disease | 2 | 2005 | 968 | 0.030 |
Why?
| | Leadership | 1 | 2011 | 120 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2011 | 271 | 0.030 |
Why?
| | Clone Cells | 1 | 2010 | 305 | 0.030 |
Why?
| | Interpersonal Relations | 1 | 2011 | 180 | 0.030 |
Why?
| | Molecular Weight | 1 | 2009 | 372 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 898 | 0.020 |
Why?
| | Ethics, Medical | 1 | 2011 | 311 | 0.020 |
Why?
| | Vaccination | 1 | 2010 | 228 | 0.020 |
Why?
| | Administration, Oral | 1 | 2009 | 726 | 0.020 |
Why?
| | Cholesterol | 1 | 2009 | 438 | 0.020 |
Why?
| | Intraoperative Period | 1 | 2007 | 102 | 0.020 |
Why?
| | Colitis, Ulcerative | 1 | 2013 | 692 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 3709 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2010 | 862 | 0.020 |
Why?
| | Acidosis, Renal Tubular | 1 | 2005 | 11 | 0.020 |
Why?
| | Mesenteric Artery, Superior | 1 | 2005 | 21 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2010 | 1906 | 0.020 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2005 | 78 | 0.020 |
Why?
| | RNA, Complementary | 1 | 2004 | 9 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2010 | 544 | 0.020 |
Why?
| | Xenopus laevis | 1 | 2005 | 142 | 0.020 |
Why?
| | Kidney Tubules, Proximal | 1 | 2005 | 67 | 0.020 |
Why?
| | Phenylalanine | 1 | 2004 | 41 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2004 | 120 | 0.020 |
Why?
| | Immunotherapy | 1 | 2010 | 578 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2011 | 2299 | 0.020 |
Why?
| | Xenopus | 1 | 2004 | 130 | 0.020 |
Why?
| | Membranes | 1 | 2004 | 39 | 0.020 |
Why?
| | Subcellular Fractions | 1 | 2004 | 100 | 0.020 |
Why?
| | Cytoplasm | 1 | 2005 | 286 | 0.020 |
Why?
| | Oocytes | 1 | 2005 | 229 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2004 | 282 | 0.020 |
Why?
| | Stress Fibers | 1 | 2003 | 24 | 0.020 |
Why?
| | Ligation | 1 | 2003 | 57 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2010 | 1613 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2004 | 302 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1605 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2005 | 737 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2004 | 303 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2005 | 276 | 0.020 |
Why?
| | Gene Deletion | 1 | 2004 | 346 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2003 | 310 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2004 | 449 | 0.020 |
Why?
| | Pain Measurement | 1 | 2003 | 304 | 0.010 |
Why?
| | Transfection | 1 | 2004 | 943 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2004 | 766 | 0.010 |
Why?
| | Intraoperative Complications | 1 | 2003 | 191 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1064 | 0.010 |
Why?
| | Analgesics, Opioid | 1 | 2005 | 374 | 0.010 |
Why?
| | Pain | 1 | 2003 | 360 | 0.010 |
Why?
| | Peptides | 1 | 2003 | 640 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1182 | 0.010 |
Why?
| | Cohort Studies | 1 | 2005 | 2710 | 0.010 |
Why?
| | DNA | 1 | 2004 | 1305 | 0.010 |
Why?
| | Mutation | 1 | 2004 | 3862 | 0.010 |
Why?
|
|
Matthews's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|